论文部分内容阅读
目的观察凯时联合贝那普利治疗早期糖尿病肾病的疗效。方法将60例2型糖尿病早期肾病患者随机分为对照组和治疗组,对照组给予贝那普利10?,每日一次,2周为1疗程;治疗组在对照组治疗的基础上,给予凯时注射液10ug加入生理盐水100m l静脉滴注,每日1次,疗程2周。比较治疗前后血压、空腹血糖(FPG)、尿素氮(BUN)、尿白蛋白排泄率(UAER)和血内生肌酐清除率(CCR)的变化。结果两组用药均可使早期DN血压下降(P<0.05)、尿自蛋白排泄率下降(P<0.05);但治疗组与对照组比较,降低尿白蛋白排泄率(UAER)具有明显差异(P<0.01),升高血内生肌酐清除率(CCR),差异有显著性(P<0.05)。结论凯时联合贝那普利治疗早期糖尿病肾病有很好的治疗效果。
Objective To observe the curative effect of Kai combined with benazepril in the treatment of early diabetic nephropathy. Methods Sixty patients with type 2 diabetes mellitus with early nephropathy were randomly divided into control group and treatment group. The control group was given benazepril 10 ?, once a day for 2 weeks for one course of treatment. On the basis of the treatment of the control group, Kay injection 10ug saline 100ml infusion, 1 day, treatment for 2 weeks. The changes of blood pressure, fasting blood glucose (FPG), blood urea nitrogen (BUN), urinary albumin excretion rate (UAER) and endogenous creatinine clearance rate (CCR) were compared before and after treatment. Results Compared with the control group, the urinary albumin excretion rate (UAER) was significantly decreased in both groups (P <0.05) and urine excretion rate (P <0.05) P <0.01), and elevated blood creatinine clearance rate (CCR), the difference was significant (P <0.05). Conclusions Kay when combined with benazepril treatment of early diabetic nephropathy has a good therapeutic effect.